Clean Yield Group Lowers Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Clean Yield Group cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 20.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 286,556 shares of the company's stock after selling 73,535 shares during the quarter. Takeda Pharmaceutical makes up 1.4% of Clean Yield Group's investment portfolio, making the stock its 23rd largest position. Clean Yield Group's holdings in Takeda Pharmaceutical were worth $4,261,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $52,000. Cromwell Holdings LLC purchased a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $61,000. Venturi Wealth Management LLC grew its holdings in Takeda Pharmaceutical by 554.7% in the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after purchasing an additional 4,260 shares during the period. Finally, Lindbrook Capital LLC grew its holdings in Takeda Pharmaceutical by 65.0% in the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $14.97 on Friday. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43. The firm has a 50 day moving average price of $14.66 and a 200 day moving average price of $14.10. The company has a market cap of $47.62 billion, a price-to-earnings ratio of 37.41, a PEG ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.